Dicerna Pharma (DRNA) Doses First Patient in of DCR-PH1 Phase 1 as PH1 Treatment
Tweet Send to a Friend
Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) announced that the Company has dosed the first patient in its DCR-PH1-101 trial, the first ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
